Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer.

Edler von Eyben F, Singh A, Zhang J, Nipsch K, Meyrick D, Lenzo N, Kairemo K, Joensuu T, Virgolini I, Soydal C, Kulkarni HR, Baum RP.

Oncotarget. 2019 Mar 29;10(25):2451-2461. doi: 10.18632/oncotarget.26789. eCollection 2019 Mar 29.

2.
3.

Comprehensive molecular imaging of malignant transformation of giant cell tumour of bone reveals diverse disease biology.

Kairemo K, Wang WL, Subbiah V.

BMJ Case Rep. 2019 Apr 23;12(4). pii: e218839. doi: 10.1136/bcr-2016-218839.

PMID:
31015231
4.

Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST.

Kairemo K, Rohren EM, Anderson PM, Ravizzini G, Rao A, Macapinlac HA, Subbiah V.

ESMO Open. 2019 Feb 28;4(1):e000439. doi: 10.1136/esmoopen-2018-000439. eCollection 2019.

5.

Is interim 18F-fluoride PET/CT a predictor of outcomes after radium-223 therapy?

Etchebehere E, Brito AE, Kairemo K, Rohren E, Araujo J, Macapinlac H.

Radiol Bras. 2019 Jan-Feb;52(1):33-40. doi: 10.1590/0100-3984.2017.0178.

6.
7.

Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.

Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren E.

Clin Cancer Res. 2019 Jul 1;25(13):3802-3810. doi: 10.1158/1078-0432.CCR-18-3964. Epub 2019 Feb 7.

PMID:
30733229
8.

Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.

Kairemo K, Milton DR, Etchebehere E, Rohren EM, Macapinlac HA.

Curr Radiopharm. 2018;11(2):147-152. doi: 10.2174/1874471011666180629145030.

PMID:
29956640
9.

Well-Founded Recommendations for Radioactive Iodine Treatment of Differentiated Thyroid Cancer Require Balanced Study of Benefits and Harms.

Tulchinsky M, Baum RP, Bennet KG, Freeman LM, Jong I, Kairemo K, Marcus CS, Moadel RM, Suman P.

J Clin Oncol. 2018 Jun 20;36(18):1887-1888. doi: 10.1200/JCO.2018.78.5972. Epub 2018 May 3. No abstract available.

PMID:
29723091
10.

Distribution of exogenous complement factor H in mice in vivo.

Koskinen AR, Cheng ZZ, Pickering MC, Kairemo K, Meri T, Cook HT, Meri S, Jokiranta TS.

Scand J Immunol. 2018 Jul;88(1):e12671. doi: 10.1111/sji.12671. Epub 2018 May 23.

11.

Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Lessons from Confronting Controversial Literature on Risks for Secondary Malignancy.

Tulchinsky M, Binse I, Campennì A, Dizdarevic S, Giovanella L, Jong I, Kairemo K, Kim CK.

J Nucl Med. 2018 May;59(5):723-725. doi: 10.2967/jnumed.118.211359. Epub 2018 Apr 13. No abstract available.

12.

Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.

von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T.

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):496-508. doi: 10.1007/s00259-017-3895-x. Epub 2017 Dec 16. Review.

13.

177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer.

von Eyben FE, Kiljunen T, Joensuu T, Kairemo K, Uprimny C, Virgolini I.

Oncotarget. 2017 Aug 2;8(39):66112-66116. doi: 10.18632/oncotarget.19805. eCollection 2017 Sep 12.

14.
15.

PET/Computed Tomography for Radiation Therapy Planning of Prostate Cancer.

Kairemo KJ.

PET Clin. 2017 Apr;12(2):257-267. doi: 10.1016/j.cpet.2016.12.003. Epub 2017 Jan 31. Review.

PMID:
28267458
16.

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives.

Subbiah V, Chuang HH, Gambhire D, Kairemo K.

Diagnostics (Basel). 2017 Feb 15;7(1). pii: E10. doi: 10.3390/diagnostics7010010.

17.

Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation.

Joensuu T, Joensuu G, Kairemo K, Kiljunen T, Riener M, Aaltonen A, Ala-Opas M, Kangasmäki A, Alanko T, Taipale L, Hervonen P, Bützow A, Virgolini I, Hemminki A.

Anticancer Res. 2016 Dec;36(12):6439-6447.

PMID:
27919966
18.

Imaging of Accidental Contamination by Fluorine-18 Solution: A Quick Troubleshooting Procedure.

Kairemo K, Kangasmäki A.

Asia Ocean J Nucl Med Biol. 2016 Winter;4(1):51-54.

19.

Letters to the Editor.

Kairemo K.

Radiat Prot Dosimetry. 2017 Apr 25;174(2):291. doi: 10.1093/rpd/ncw134. No abstract available.

PMID:
27242343
20.

Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.

von Eyben FE, Kairemo K.

Ann Nucl Med. 2016 Jul;30(6):385-92. doi: 10.1007/s12149-016-1078-7. Epub 2016 May 12. Review.

PMID:
27173771
21.

Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.

Ranki T, Pesonen S, Hemminki A, Partanen K, Kairemo K, Alanko T, Lundin J, Linder N, Turkki R, Ristimäki A, Jäger E, Karbach J, Wahle C, Kankainen M, Backman C, von Euler M, Haavisto E, Hakonen T, Heiskanen R, Jaderberg M, Juhila J, Priha P, Suoranta L, Vassilev L, Vuolanto A, Joensuu T.

J Immunother Cancer. 2016 Mar 15;4:17. doi: 10.1186/s40425-016-0121-5. eCollection 2016.

22.
23.

Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics.

Kairemo K, Joensuu T, Rasulova N, Kiljunen T, Kangasmäki A.

Diagnostics (Basel). 2015 Jul 30;5(3):358-68. doi: 10.3390/diagnostics5030358.

24.

Radiotherapy Boost for the Dominant Intraprostatic Cancer Lesion-A Systematic Review and Meta-Analysis.

von Eyben FE, Kiljunen T, Kangasmaki A, Kairemo K, von Eyben R, Joensuu T.

Clin Genitourin Cancer. 2016 Jun;14(3):189-97. doi: 10.1016/j.clgc.2015.12.005. Epub 2015 Dec 17. Review.

PMID:
26768965
25.

Volumetric Modulated Arc Therapy Planning For Primary Prostate Cancer With Selective Intraprostatic Boost Determined By (18) f-Choline PET-CT: In Regard to Kuang et al.

von Eyben FE, Kiljunen T, Kangasmaki A, Kairemo K, von Eyben R, Joensuu T.

Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):466-7. doi: 10.1016/j.ijrobp.2015.06.008. No abstract available.

PMID:
26383684
26.

Management of advanced prostate cancer.

von Eyben F, Kiljunen T, Kangasmaki A, Kairemo K, von Eyben R, Joensuu T.

Ann Oncol. 2015 Nov;26(11):2354. doi: 10.1093/annonc/mdv327. Epub 2015 Jul 27. No abstract available.

PMID:
26216387
27.

Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer.

Vassilev L, Ranki T, Joensuu T, Jäger E, Karbach J, Wahle C, Partanen K, Kairemo K, Alanko T, Turkki R, Linder N, Lundin J, Ristimäki A, Kankainen M, Hemminki A, Backman C, Dienel K, von Euler M, Haavisto E, Hakonen T, Juhila J, Jäderberg M, Priha P, Vuolanto A, Pesonen S.

Oncoimmunology. 2015 Apr 1;4(7):e1017702. eCollection 2015 Jul.

28.

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy.

Liikanen I, Koski A, Merisalo-Soikkeli M, Hemminki O, Oksanen M, Kairemo K, Joensuu T, Kanerva A, Hemminki A.

Oncoimmunology. 2015 Apr 2;4(3):e989771. eCollection 2015 Mar.

29.

Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization.

Ranki T, Joensuu T, Jäger E, Karbach J, Wahle C, Kairemo K, Alanko T, Partanen K, Turkki R, Linder N, Lundin J, Ristimäki A, Kankainen M, Hemminki A, Backman C, Dienel K, von Euler M, Haavisto E, Hakonen T, Juhila J, Jaderberg M, Priha P, Vassilev L, Vuolanto A, Pesonen S.

Oncoimmunology. 2014 Dec 15;3(10):e958937. eCollection 2014 Nov.

30.

PET/CT Dose Planning for Volumetric Modulated Arc Radiation Therapy (VMAT) -Comparison with Conventional Approach in Advanced Prostate Cancer Patients.

Kairemo K, Rasulova N, Kiljunen T, Partanen K, Kangasmäki A, Joensuu T.

Curr Radiopharm. 2015;8(1):2-8.

PMID:
25882786
31.

Hypoxia PET Tracers in EBRT Dose Planning in Head and Neck Cancer.

Hodolič M, Fettich J, Kairemo K.

Curr Radiopharm. 2015;8(1):32-7. Review.

PMID:
25808959
32.

Planning of External Beam Radiotherapy for Prostate Cancer Guided by PET/CT.

von Eyben FE, Kairemo K, Kiljunen T, Joensuu T.

Curr Radiopharm. 2015;8(1):19-31. Review.

PMID:
25808958
33.

PET/CT in External Beam Radiation Therapy Dose Planning.

Kairemo K.

Curr Radiopharm. 2015;8(1):1. No abstract available.

PMID:
25808956
34.

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.

Hemminki O, Parviainen S, Juhila J, Turkki R, Linder N, Lundin J, Kankainen M, Ristimäki A, Koski A, Liikanen I, Oksanen M, Nettelbeck DM, Kairemo K, Partanen K, Joensuu T, Kanerva A, Hemminki A.

Oncotarget. 2015 Feb 28;6(6):4467-81.

35.

VMAT technique enables concomitant radiotherapy of prostate cancer and pelvic bone metastases.

Kiljunen T, Kangasmäki A, Aaltonen A, Kairemo K, Partanen K, Joensuu G, Alanko T, Vaalavirta L, Joensuu T.

Acta Oncol. 2015 Jun;54(6):847-53. doi: 10.3109/0284186X.2014.962665. Epub 2014 Oct 13.

PMID:
25307406
36.
37.

Preliminary clinical experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT imaging in prostate cancer patients.

Kairemo K, Rasulova N, Partanen K, Joensuu T.

Biomed Res Int. 2014;2014:305182. doi: 10.1155/2014/305182. Epub 2014 Jun 1.

38.

Adjuvant radiotherapy for lymph-node positive prostate cancer.

von Eyben FE, Kairemo K, Kiljunen T, Joensuu T.

BJU Int. 2015 Mar;115(3):353-5. doi: 10.1111/bju.12659. Epub 2014 May 22. No abstract available.

39.

Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer.

von Eyben FE, Kairemo K.

Nucl Med Commun. 2014 Mar;35(3):221-30. doi: 10.1097/MNM.0000000000000040.

PMID:
24240194
40.

[(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer.

Koski A, Ahtinen H, Liljenback H, Roivainen A, Koskela A, Oksanen M, Partanen K, Laasonen L, Kairemo K, Joensuu T, Hemminki A.

Hum Gene Ther. 2013 Dec;24(12):1029-41. doi: 10.1089/hum.2013.123. Epub 2013 Nov 7.

PMID:
24099555
41.

In vivo targeting of activated leukocytes by a β2-integrin binding peptide.

Ranta TM, Suojanen J, Peñate-Medina O, Will O, Tower RJ, Glüer C, Kairemo K, Gahmberg CG, Koivunen E, Sorsa T, Saris PE, Reunanen J.

Mol Diagn Ther. 2014 Feb;18(1):39-44. doi: 10.1007/s40291-013-0052-5.

PMID:
23982749
42.

Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.

Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, Tähtinen S, Oksanen M, Heiskanen R, Pesonen S, Joensuu T, Alanko T, Partanen K, Laasonen L, Kairemo K, Pesonen S, Kangasniemi L, Hemminki A.

Clin Cancer Res. 2013 May 15;19(10):2734-44. doi: 10.1158/1078-0432.CCR-12-2546. Epub 2013 Mar 14.

43.

Nuclear medicine in Finland.

Kairemo K.

World J Nucl Med. 2012 Sep;11(3):101-2. doi: 10.4103/1450-1147.103406. No abstract available.

44.

[¹⁸F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography imaging in oncology: initial staging and evaluation of cancer therapy.

Pauwels EK, Coumou AW, Kostkiewicz M, Kairemo K.

Med Princ Pract. 2013;22(5):427-37. doi: 10.1159/000346303. Epub 2013 Jan 26. Review.

45.

4D SPECT/CT acquisition for 3D dose calculation and dose planning in (177)Lu-peptide receptor radionuclide therapy: applications for clinical routine.

Kairemo K, Kangasmäki A.

Recent Results Cancer Res. 2013;194:537-50. doi: 10.1007/978-3-642-27994-2_31.

PMID:
22918781
46.

Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.

Hemminki O, Diaconu I, Cerullo V, Pesonen SK, Kanerva A, Joensuu T, Kairemo K, Laasonen L, Partanen K, Kangasniemi L, Lieber A, Pesonen S, Hemminki A.

Mol Ther. 2012 Sep;20(9):1821-30. doi: 10.1038/mt.2012.115. Epub 2012 Aug 7.

47.

SPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131I.

Rajecki M, Sarparanta M, Hakkarainen T, Tenhunen M, Diaconu I, Kuhmonen V, Kairemo K, Kanerva A, Airaksinen AJ, Hemminki A.

PLoS One. 2012;7(3):e32871. doi: 10.1371/journal.pone.0032871. Epub 2012 Mar 7.

48.

Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients.

Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva A, Pesonen SK, Gerdemann U, Leen AM, Kairemo K, Oksanen M, Haavisto E, Holm SL, Karioja-Kallio A, Kauppinen S, Partanen KP, Laasonen L, Joensuu T, Alanko T, Cerullo V, Hemminki A.

Cancer Res. 2012 Apr 1;72(7):1621-31. doi: 10.1158/0008-5472.CAN-11-3001. Epub 2012 Feb 9.

49.

Liposomal Tumor Targeting in Drug Delivery Utilizing MMP-2- and MMP-9-Binding Ligands.

Penate Medina O, Haikola M, Tahtinen M, Simpura I, Kaukinen S, Valtanen H, Zhu Y, Kuosmanen S, Cao W, Reunanen J, Nurminen T, Saris PE, Smith-Jones P, Bradbury M, Larson S, Kairemo K.

J Drug Deliv. 2011;2011:160515. doi: 10.1155/2011/160515. Epub 2010 Dec 29.

50.

Sodium iodide symporter SPECT imaging of a patient treated with oncolytic adenovirus Ad5/3-Δ24-hNIS.

Rajecki M, Kangasmäki A, Laasonen L, Escutenaire S, Hakkarainen T, Haukka J, Ristimäki A, Kairemo K, Kangasniemi L, Kiljunen T, Joensuu T, Pesonen S, Hemminki A.

Mol Ther. 2011 Apr;19(4):629-31. doi: 10.1038/mt.2011.31. No abstract available.

Supplemental Content

Loading ...
Support Center